Aterovax is an emerging biopharmaceutical company dedicated to one specific target : improving the management of diagnostic, prognosis and treatment of atherosclerosis, main process responsible for important vascular events including coronary artery disease, stroke and peripheral arterial disease.

So far, no existing therapy targets directly the atherosclerotic plates. Our ambition is to fulfill this unmet medical need.